CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) surged 6.28% to HKD 97.760
Newtimespace News, as of 10:29 on May 13, CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) was quoted at HKD 97.760, up 6.28%. The ETF opened at HKD 95.040, with a high of HKD 98.900 and a low of HKD 95.040. The latest NAV per unit is HKD 90.402, with a premium rate of 1.75%. The asset size is approximately HKD 48.457 billion.
CSOP SK Hynix Daily (2x) Leveraged Product(07709.HK) is a leveraged ETF that tracks an index linked to the share price performance of the South Korean tech giant SK Hynix. The investment objective of this product is to provide a return equivalent to twice the daily return of the underlying asset. As a leading global semiconductor manufacturer, SK Hynix holds a core position in the DRAM and NAND flash memory markets. Its share price performance is highly correlated with the global semiconductor industry cycle and artificial intelligence (AI) demand. Such leveraged products are suitable for short-term tactical trading, but investors should be aware of the amplified volatility risks associated with leverage.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CHI MER LAND (00978.HK): JV bid of HKD 1.03 billion for Hung Shui Kiu land accepted, constituting discloseable transaction under alternative size test
- TST PROPERTIES & SINO LAND (00247.HK/00083.HK): Consortium bid of HKD 1.03 billion for Hung Shui Kiu land accepted, JVs established for acquisition and development
- BANK OF CHINA (03988.HK): Completes issuance of RMB 20 billion write-down perpetual capital bonds at coupon rate of 1.86%
- CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
- TAI SANG LAND(00089.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 48.32 million, turned profitable from a loss YoY